Balyasny Asset Management
VYGR icon

Balyasny Asset Management’s Voyager Therapeutics VYGR Stock Holding History

Balyasny Asset Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-129,600
Closed -$3.59M – 1627
2019
Q2 		$3.59M Buy
+129,600
New +$2.97M 0.02% 707

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Balyasny Asset Management's VYGR Position: Q2 2024 in Review

Balyasny Asset Management sold out of Voyager Therapeutics (VYGR) in Q2 2024, closing a stake of 21,341 shares — an estimated $199K sold.

Balyasny Asset Management first reported a position in VYGR in Q4 2017 and held it in 6 quarters. The position peaked at $2.72M in Q4 2017. 127 funds tracked by Wall St. Rank hold VYGR as of Q2 2024.

  • Balyasny Asset Management reported no remaining Voyager Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 21,341 Voyager Therapeutics shares in Q2 2024, an estimated $199K.
  • Balyasny Asset Management first reported a position in Voyager Therapeutics in Q4 2017 and held it in 6 quarters.
  • Balyasny Asset Management's Voyager Therapeutics position peaked at $2.72M in Q4 2017.
  • 127 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.